MX2016003861A - Nuevos derivados de 1-(4-pirimidinil)-1h-pirrolo[3,2-c]piridina como inhibidores de la cinasa inductora de nf-kappab. - Google Patents
Nuevos derivados de 1-(4-pirimidinil)-1h-pirrolo[3,2-c]piridina como inhibidores de la cinasa inductora de nf-kappab.Info
- Publication number
- MX2016003861A MX2016003861A MX2016003861A MX2016003861A MX2016003861A MX 2016003861 A MX2016003861 A MX 2016003861A MX 2016003861 A MX2016003861 A MX 2016003861A MX 2016003861 A MX2016003861 A MX 2016003861A MX 2016003861 A MX2016003861 A MX 2016003861A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- pirimidinil
- pirrolo
- kappab
- kinase
- Prior art date
Links
- 230000001939 inductive effect Effects 0.000 title abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101001005550 Homo sapiens Mitogen-activated protein kinase kinase kinase 14 Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102100025211 Mitogen-activated protein kinase kinase kinase 14 Human genes 0.000 abstract 1
- 102000003945 NF-kappa B Human genes 0.000 abstract 1
- 108010057466 NF-kappa B Proteins 0.000 abstract 1
- 102000019148 NF-kappaB-inducing kinase activity proteins Human genes 0.000 abstract 1
- 108040008091 NF-kappaB-inducing kinase activity proteins Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a agentes farmacéuticos útiles para la terapia y/o profilaxis en un mamífero, y en particular a inhibidores de la cinasa inductora de NF-kB (NIK - también conocida como MAP3K14) útiles para tratar enfermedades tales como el cáncer, trastornos inflamatorios, trastornos metabólicos y trastornos autoinmunitarios; la invención también se refiere a composiciones farmacéuticas que comprenden tales compuestos, a procesos para preparar tales compuestos y composiciones, y al uso de tales compuestos o composiciones farmacéuticas para prevenir o tratar enfermedades tales como el cáncer, trastornos inflamatorios, trastornos metabólicos, incluidas la obesidad y la diabetes, y trastornos autoinmunitarios.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13186139 | 2013-09-26 | ||
EP14176121 | 2014-07-08 | ||
PCT/EP2014/070484 WO2015044267A1 (en) | 2013-09-26 | 2014-09-25 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016003861A true MX2016003861A (es) | 2016-07-26 |
MX373186B MX373186B (es) | 2025-03-05 |
Family
ID=51619194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016003861A MX373186B (es) | 2013-09-26 | 2014-09-25 | Nuevos derivados de 1-(4-pirimidinil)-1h-pirrolo[3,2-c]piridina como inhibidores de la cinasa inductora de nf-kappab. |
Country Status (15)
Country | Link |
---|---|
US (1) | US10005773B2 (es) |
EP (1) | EP3071566B1 (es) |
JP (1) | JP6402179B2 (es) |
KR (1) | KR102317334B1 (es) |
CN (1) | CN105579451B (es) |
AU (1) | AU2014327233B2 (es) |
BR (1) | BR112016005914A2 (es) |
CA (1) | CA2922753C (es) |
EA (1) | EA029595B1 (es) |
ES (1) | ES2804595T3 (es) |
HK (1) | HK1224295A1 (es) |
IL (1) | IL244706B (es) |
MX (1) | MX373186B (es) |
TW (1) | TWI704146B (es) |
WO (1) | WO2015044267A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI663166B (zh) | 2013-04-24 | 2019-06-21 | 健生藥品公司 | 新化合物 |
TWI704146B (zh) | 2013-09-26 | 2020-09-11 | 比利時商健生藥品公司 | 用作NIK抑制劑之新的1-(4-嘧啶基)-1H-吡唑並[3,2-c]吡啶衍生物 |
TWI627173B (zh) | 2013-09-26 | 2018-06-21 | 比利時商健生藥品公司 | 作為NIK抑制劑的新穎3-(1H-吡唑-4-基)-1H-吡咯并[2,3-c]吡啶衍生物 |
BR112017008039B1 (pt) | 2014-10-23 | 2023-04-11 | Janssen Pharmaceutica N.V. | Derivados de pirazol como inibidores de nik, seu uso no tratamento ou prevenção de câncer e composição farmacêutica que os compreende |
BR112017007704B1 (pt) | 2014-10-23 | 2023-04-11 | Janssen Pharmaceutica N.V | Derivados de pirazolopirimidina como inibidores de nik, seu uso e composição farmacêutica que os compreende |
WO2016062792A1 (en) | 2014-10-23 | 2016-04-28 | Janssen Pharmaceutica Nv | New compounds as nik inhibitors |
US10323045B2 (en) | 2014-10-23 | 2019-06-18 | Janssen Pharmaceutica Nv | Thienopyrimidine derivatives as NIK inhibitors |
BR112018014675B1 (pt) | 2016-01-22 | 2023-12-19 | Janssen Pharmaceutica Nv | Derivados de cianoindolina substituída como inibidores de nik e composição farmacêutica que os compreende |
CN109311846B (zh) * | 2016-01-22 | 2021-03-19 | 杨森制药有限公司 | 作为nik抑制剂的新的6元杂芳族取代的氰基吲哚衍生物 |
US20190119299A1 (en) * | 2016-06-30 | 2019-04-25 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as nik inhibitors |
US11136311B2 (en) | 2016-06-30 | 2021-10-05 | Janssen Pharmaceutica Nv | Heteroaromatic derivatives as NIK inhibitors |
JP7138093B2 (ja) * | 2016-08-24 | 2022-09-15 | エフ.ホフマン-ラ ロシュ アーゲー | 2-アザビシクロ[3.1.0]ヘキサン-3-オン誘導体及び使用方法 |
JP7140751B2 (ja) * | 2016-08-24 | 2022-09-21 | エフ.ホフマン-ラ ロシュ アーゲー | 2-アザビシクロ[3.1.0]ヘキサン-3-オン誘導体及び使用方法 |
MX2021014679A (es) | 2019-05-31 | 2022-04-06 | Janssen Pharmaceutica Nv | Inhibidores de molécula pequeña de quinasa inductora de nf-kb. |
CN113816957B (zh) * | 2021-10-29 | 2023-04-07 | 浙江工业大学 | 4-(7-氮杂吲哚)-2-氨基嘧啶类化合物及其应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3990061B2 (ja) * | 1998-01-05 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プリン誘導体および糖尿病の予防・治療剤としてのアデノシンa2受容体拮抗剤 |
CA2564356A1 (en) | 2004-04-26 | 2005-11-03 | Pfizer Inc. | Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors |
AR056786A1 (es) * | 2005-11-10 | 2007-10-24 | Smithkline Beecham Corp | Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com |
DE102008005493A1 (de) | 2008-01-22 | 2009-07-23 | Merck Patent Gmbh | 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate |
WO2009158011A1 (en) * | 2008-06-26 | 2009-12-30 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
WO2010003133A2 (en) | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
WO2010042337A1 (en) * | 2008-10-07 | 2010-04-15 | Merck Sharp & Dohme Corp. | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
CN101723936B (zh) | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
WO2011050245A1 (en) * | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
US8901313B2 (en) * | 2011-03-16 | 2014-12-02 | Genentech, Inc. | 6,5-heterocyclic propargylic alcohol compounds and uses therefor |
TWI663166B (zh) * | 2013-04-24 | 2019-06-21 | 健生藥品公司 | 新化合物 |
TWI627173B (zh) * | 2013-09-26 | 2018-06-21 | 比利時商健生藥品公司 | 作為NIK抑制劑的新穎3-(1H-吡唑-4-基)-1H-吡咯并[2,3-c]吡啶衍生物 |
TWI704146B (zh) | 2013-09-26 | 2020-09-11 | 比利時商健生藥品公司 | 用作NIK抑制劑之新的1-(4-嘧啶基)-1H-吡唑並[3,2-c]吡啶衍生物 |
BR112017008039B1 (pt) | 2014-10-23 | 2023-04-11 | Janssen Pharmaceutica N.V. | Derivados de pirazol como inibidores de nik, seu uso no tratamento ou prevenção de câncer e composição farmacêutica que os compreende |
WO2016062792A1 (en) | 2014-10-23 | 2016-04-28 | Janssen Pharmaceutica Nv | New compounds as nik inhibitors |
BR112017007704B1 (pt) | 2014-10-23 | 2023-04-11 | Janssen Pharmaceutica N.V | Derivados de pirazolopirimidina como inibidores de nik, seu uso e composição farmacêutica que os compreende |
US10323045B2 (en) | 2014-10-23 | 2019-06-18 | Janssen Pharmaceutica Nv | Thienopyrimidine derivatives as NIK inhibitors |
-
2014
- 2014-09-24 TW TW103132898A patent/TWI704146B/zh not_active IP Right Cessation
- 2014-09-25 BR BR112016005914A patent/BR112016005914A2/pt not_active Application Discontinuation
- 2014-09-25 ES ES14772372T patent/ES2804595T3/es active Active
- 2014-09-25 EA EA201690645A patent/EA029595B1/ru not_active IP Right Cessation
- 2014-09-25 KR KR1020167007899A patent/KR102317334B1/ko active Active
- 2014-09-25 JP JP2016517332A patent/JP6402179B2/ja active Active
- 2014-09-25 WO PCT/EP2014/070484 patent/WO2015044267A1/en active Application Filing
- 2014-09-25 CN CN201480052786.XA patent/CN105579451B/zh active Active
- 2014-09-25 EP EP14772372.0A patent/EP3071566B1/en active Active
- 2014-09-25 US US15/024,603 patent/US10005773B2/en active Active
- 2014-09-25 CA CA2922753A patent/CA2922753C/en active Active
- 2014-09-25 AU AU2014327233A patent/AU2014327233B2/en not_active Ceased
- 2014-09-25 MX MX2016003861A patent/MX373186B/es active IP Right Grant
-
2016
- 2016-03-22 IL IL244706A patent/IL244706B/en active IP Right Grant
- 2016-11-04 HK HK16112697.3A patent/HK1224295A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN105579451B (zh) | 2017-10-27 |
KR102317334B1 (ko) | 2021-10-26 |
IL244706A0 (en) | 2016-04-21 |
EP3071566A1 (en) | 2016-09-28 |
JP2016531868A (ja) | 2016-10-13 |
US20160257679A1 (en) | 2016-09-08 |
EA029595B1 (ru) | 2018-04-30 |
BR112016005914A2 (pt) | 2017-08-01 |
HK1224295A1 (zh) | 2017-08-18 |
AU2014327233B2 (en) | 2018-03-01 |
TWI704146B (zh) | 2020-09-11 |
AU2014327233A1 (en) | 2016-03-10 |
CN105579451A (zh) | 2016-05-11 |
ES2804595T3 (es) | 2021-02-08 |
CA2922753A1 (en) | 2015-04-02 |
US10005773B2 (en) | 2018-06-26 |
EA201690645A1 (ru) | 2016-08-31 |
KR20160058814A (ko) | 2016-05-25 |
JP6402179B2 (ja) | 2018-10-10 |
IL244706B (en) | 2021-02-28 |
WO2015044267A1 (en) | 2015-04-02 |
TW201602104A (zh) | 2016-01-16 |
CA2922753C (en) | 2021-08-17 |
EP3071566B1 (en) | 2020-04-15 |
MX373186B (es) | 2025-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016003861A (es) | Nuevos derivados de 1-(4-pirimidinil)-1h-pirrolo[3,2-c]piridina como inhibidores de la cinasa inductora de nf-kappab. | |
PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
MX2016003863A (es) | Nuevos derivados de 3-(1h-pirazol-4-il)-1h-pirrolo[2,3-c]piridina como inhibidores de la cinasa inductora de nf-kappab. | |
MX2017005283A (es) | Nuevos derivados de pirazol en calidad de inhibidores de la cinasa inductora de nf-kb (nik). | |
MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
WO2014194254A9 (en) | Treatment of cancers using pi3 kinase isoform modulators | |
CU20130115A7 (es) | Compuestos y composiciones como inhibidores de trk | |
CL2013001093A1 (es) | Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer . | |
CO6870032A2 (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
MX2015012502A (es) | Inhibidores de proteina cinasa dependiente de adn. | |
MX2015012867A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
BR112015026721A2 (pt) | derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1h-pirrolo[2,3-c]piridina como inibidores de nik para o tratamento de câncer | |
PH12018501567A1 (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
BR112017008045A2 (pt) | compostos como inibidores de nik | |
MY181602A (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
MX2017005285A (es) | Nuevos derivados de tienopirimidina en calidad de inhibidores de la cinasa inductora de nf-kb (nik). | |
MX2017005284A (es) | Nuevos derivados de pirazolopirimidina de la cinasa inductora de nf-kb (nk). | |
CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
MX364859B (es) | Derivados de imidazopirazinona. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |